E 64c

Category	SARS-CoV
CAS	76684-89-4
Description	E-64c is a cysteine protease inhibitor used for detecting autophagy in plants.

Quotation Now

Product Information

Synonyms	Loxistatin acid
IUPAC Name	(2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid
Molecular Weight	314.38
Molecular Formula	C15H26N2O5
Canonical SMILES	CC(C)CCNC(=O)C(CC(C)C)NC(=O)C1C(O1)C(=O)O
InChI	InChI=1S/C15H26N2O5/c1-8(2)5-6-16-13(18)10(7-9(3)4)17-14(19)11-12(22-11)15(20)21/h8-12H,5-7H2,1-4H3,(H,16,18)(H,17,19)(H,20,21)/t10-,11-,12-/m0/s1
InChIKey	SCMSYZJDIQPSDI-SRVKXCTJSA-N
Boiling Point	596.4±50.0 °C at 760 mmHg
Flash Point	314.5±30.1 °C
Purity	98%
Density	1.2±0.1 g/cm3
Solubility	In Vitro: DMSO : 250 mg/mL(795.22 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (6.62 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (6.62 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.08 mg/mL (6.62 mM); Clear solution
Appearance	White to off-white (Solid)
Storage	Store at 2-8°C
Complexity	422
Exact Mass	314.18417193
Index Of Refraction	1.504
In Vitro	E-64c, a derivative of naturally occurring epoxide inhibitor of cysteine proteases, with papain; especially with regard to the hydrogen bonding and hydrophobic interactions of the ligands with conserved residues in the catalytic binding site. E 64c (k2/Ki=140±5M-1s-1) is demonstrated to be a lead structure for the development of irreversible cathepsin C inhibitors.
In Vivo	The t-1/2 of plasma E-64c is 0.48 hours. The hemodynamic effects of E-64c are absent at this dose. Using two way analysis of variance, the effects of reperfusion (p=0.0016) or E-64c (p=0.0226) per se on infarct size are significant. In comparing Group A with Group B and Group C with Group D, the depletion of CPK in the E-64c treated groups (Groups A and C) is slightly less than in the vehicle-injected groups (Groups B and D). The insufficient effect of E-64c alone may be explained by the early administration and relatively short t-1/2. Since the effectiveness of NCO-700 has been established,6),7) our findings might indicate a small but beneficial effect of E-64c on infarct size and CPK content.
PSA	108.03000
Target	Cysteine proteases, CANP, Cathepsin C; SARS-CoV
Vapor Pressure	0.0±3.6 mmHg at 25°C
XLogP3-AA	1.6